Related Experiment Video
Updated: Mar 25, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
14.0K
A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma
CPT: Pharmacometrics & Systems Pharmacology
|February 24, 2016
Summary
Longitudinal tumor growth inhibition (TGI) modeling accurately predicts outcomes in multiple myeloma (MM). Early change in tumor size (ECTS) at week 4 is a significant predictor of overall survival in MM patients treated with carfilzomib.
Area of Science:
- Oncology
- Pharmacometrics
- Biostatistics
Background:
- Longitudinal tumor growth inhibition (TGI) modeling is a validated predictive biomarker for clinical outcomes across various cancer types.
- Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
- Early assessment of treatment response is crucial for optimizing patient management in relapsed/refractory MM.
Purpose of the Study:
- To apply TGI modeling to M-protein data for subjects with multiple myeloma (MM).
- To evaluate early change in tumor size (ECTS) as a predictive biomarker for overall survival in MM patients.
- To identify key predictors of overall survival in MM patients receiving single-agent carfilzomib.
Main Methods:
- Longitudinal M-protein data from 456 relapsed/refractory MM subjects treated with carfilzomib were analyzed using TGI modeling.
- A tumor growth rate was estimated to assess model robustness and treatment independence.
- An overall survival model was developed incorporating ECTS and other clinical variables.
Main Results:
- The TGI model demonstrated robustness and treatment independence, with estimated tumor growth rates comparable to other anti-myeloma agents.
- Early change in tumor size (ECTS) at week 4 was identified as a significant independent predictor of overall survival.
- Other significant predictors of overall survival included ECOG performance status, hemoglobin, sex, bone marrow involvement, and prior regimens (P < 0.001).
Conclusions:
- Longitudinal tumor growth inhibition (TGI) modeling, using M-protein levels, is applicable and robust for multiple myeloma (MM).
- Early change in tumor size (ECTS) derived from M-protein modeling serves as a promising early biomarker for predicting overall survival in MM patients.
- ECTS, alongside established prognostic factors, can aid in risk stratification and treatment decisions for MM patients receiving carfilzomib.
